Poor
Mostly Aligned
Patient Risk:
Low
Summary
Overall alignment is poor due to numerous acne-related efficacy/dosing claims not supported by the label, while several label-supported safety statements are present. Some on-label points (aldosterone antagonism, hyperkalemia monitoring, pregnancy-related contraindications, and adverse reactions) align, but the majority of off-label acne claims are unsupported.
Category Scores
Accurate Statements
Spironolactone is an aldosterone antagonist.
12.1
Hyperkalemia (monitor potassium levels).
5.1
Rare risks: low blood pressure.
5.2
Rare risks: kidney issues.
5.2, 6
Contraindicated in pregnancy.
8.1
Contraindicated in Addison's disease.
4
Contraindicated in hyperkalemia.
4, 5.1
Spironolactone has side effects.
6
Breast tenderness (20-30%).
6
Unsupported Statements
Spironolactone helps treat hormonal acne in many patients, especially women with acne linked to androgen excess.
Not supported by label; acne indication not present.
It reduces testosterone production.
Not supported by label.
It lowers sebum output.
Not supported by label.
It lowers inflammation that drive acne on the jawline, chin, and lower face.
Not supported by label.
Dermatologists use it off-label at 50-200 mg daily for acne.
Not supported by label; off-label dosing not part of labeling.
It cuts androgen activity by 30-50% in skin.
Not supported by label.
It shrinks oil glands.
Not supported by label.
It prevents pore clogs over 3-6 months.
Not supported by label.
Women aged 20-40 with persistent, cyclical acne unresponsive to topical treatments or birth control benefit.
Not supported by label.
It's ineffective for men due to gynecomastia risk.
Not supported by label.
It's less common in teens with pubertal acne.
Not supported by label.
Studies show 50-70% improvement in moderate-to-severe cases after 6 months.
Not supported by label.
A 2018 review of 9 trials (649 patients) found spironolactone cleared acne in 52%.
Not supported by label.
A 2018 review found it reduced lesions by 50% at 100 mg doses.
Not supported by label.
A 2020 meta-analysis confirmed similar results.
Not supported by label.
A 2020 meta-analysis found better outcomes when combined with topicals like retinoids.
Not supported by label.
No large head-to-head trials exist against isotretinoin.
Not supported by label.
It's milder for long-term use.
Not supported by label.
Frequent urination is a common side effect.
Not clearly described in label.
Birth defects—requires contraception.
Not supported by label.
Avoid in breastfeeding.
Not clearly stated in label subset.
Spironolactone has a 50-70% response.
Not supported by label.
Spironolactone provides oral, long-term control.
Not supported by label.
Contraception is needed.
Not supported by label.
Oral contraceptives (e.g., Yaz) have moderate-high effectiveness.
Not a spironolactone labeling claim.
Oral contraceptives regulate cycles.
Not a spironolactone labeling claim.
Oral contraceptives have a blood clot risk.
Not a spironolactone labeling claim.
Oral contraceptives are moderate-high in effectiveness.
Not a spironolactone labeling claim.
Oral contraceptives are less potent for severe acne.
Not a spironolactone labeling claim.
Isotretinoin (Accutane) has the highest 80-90% response rate.
Not a spironolactone labeling claim.
Isotretinoin often yields permanent remission.
Not a spironolactone labeling claim.
Isotretinoin is teratogenic.
Not a spironolactone labeling claim.
Isotretinoin causes dry skin.
Not a spironolactone labeling claim.
Isotretinoin requires monitoring.
Not a spironolactone labeling claim.
Topicals have moderate effectiveness.
Not a spironolactone labeling claim.
Topicals have no systemic risks.
Not a spironolactone labeling claim.
Topicals are slower.
Not a spironolactone labeling claim.
Topicals irritate skin.
Not a spironolactone labeling claim.
Improvement starts at 4-6 weeks.
Not described in label for acne context.
Improvement peaks at 3-6 months.
Not described in label for acne context.
Standard dose: 50-100 mg daily, split if needed.
Not described in label for acne context.
Maximum dose: 200 mg.
Not described in label for acne context.
Taper off after 1-2 years to test need.
Not described in label for acne context.
Contraindicated in breastfeeding.
Not clearly stated in label subset.
Cyproterone acetate is not FDA-approved in the US.
Not a spironolactone labeling claim.
Metformin for PCOS-linked acne.
Not a spironolactone labeling claim.
Flutamide is an alternative with higher liver risk.
Not a spironolactone labeling claim.
Contradictions
Low
AI Statement
It blocks androgen receptors.
Label Reference
12.1
Important Omissions
Acne efficacy claims and dosing for acne are not in label; lacks labeling support.
Importance:
High
Contraception guidance for acne use is not in labeling.
Importance:
Medium
Detailed consumer-facing safety warnings specific to acne use are not in labeling.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label safety concerns center on hyperkalemia, hypotension, electrolyte disturbances, and gynecomastia; acne-use claims are not supported by the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Predominant acne efficacy and dosing claims are off-label and not supported by the label; strengthen focus on labeling and clearly separate acne-related off-label information.
Suggested Improvement
Limit statements to label-supported indications and safety data; explicitly label acne efficacy as off-label and not FDA-approved for spironolactone; provide separate, non-label references for acne literature if needed.